Cash conversion cycleWarning
현금전환주기(CCC) 3기 연속 확대 — 운전자본 경색·현금 회수 지연 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Celemics
331920 · KOSDAQ₩14,470+1.19%
2026-09-04 closeCelemics last closed at ₩14,470 (+1.19%) on 2026-09-04. Listed on KOSDAQ; price, financials and dividends update daily after market close.
Loading chart…
Close
Market Leader RS 98 · top 2%
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p
Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.
Signal history
| Date | Signal | +20 trading days |
|---|---|---|
A record, not a prediction.
How this is calculated
"·" means fewer than 20 trading days have passed since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
C+
Overall: 건강관리 194/291 · top 67%
Factor composite · relative position in sector
PER 9.63 · PBR 4.35 — own-history percentile 83/100 · 12/100
Open self-history band
PER83/100
PBR12/100
Factual information · not investment advice
Past reported results · not investment advice
More — deeper indicators
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 10.15
Distress
Grey
Safe
- Altman Z''
- 10.15
- Beneish M-Score
- -0.15
- Sloan accrual
- 43.00%
Statistical manipulation-risk signal
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
5/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score5/9
Profitability
- Positive ROAPass
- Positive OCFNot passed
- Improving ΔROAPass
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtPass
- Higher current ratioNot passed
- No new sharesPass
Efficiency
- Higher gross marginPass
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Margin trendWarning
영업외손익 급변 (영업이익 대비 645% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Industry structure
KRAs of 2026-09-05건강관리
This stock is in 건강관리: revenue rank 250 of 287, share 0%.
250 / 2870%revenue share
Who dominates this industry?
- 1삼성바이오로직스7.3%
- 2셀트리온5.7%
- 3녹십자홀딩스3.5%
- 4유한양행3.3%
- 5대웅3.1%
- 6셀레믹스0%
Concentration
DistributedCR3 16.6%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 31.61
- Direction
- 확대
- Level
- 넓음
- Years
- 7
Value lens
- P90/P10
- 13.9
- Median P/B
- 1.47
- Level
- 넓음
- n
- 263
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- -28.3%
- Interest coverage
- -71.4x
- Return on equity (ROE)
- 45.1%
Operating margin −5pp
Operating lossInterest coverageBase -71.4x adverse case -84.1x
Return on equity (ROE)Base 45.1% adverse case -8.3%
Revenue −15%
Interest coverage riskInterest coverageBase -71.4x adverse case -60.7x
Return on equity (ROE)Base 45.1% adverse case -6%
Interest rate +2pp
Interest coverage riskInterest coverageBase -71.4x adverse case -26.7x
Return on equity (ROE)Base 45.1% adverse case -7.3%
Interest coverage limit
Already below the limit by 28.7ppInterest coverage limit at an operating margin of 0.4%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-03-23Suppliers disclosed by the company in its 2026-03-23 annual report.
Suppliers without disclosed amount
MiseqReagentsKitNextseqDNA
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 박종갑24.83%2026-07-21 · 증감 +0.08%p
- 수피젠 신기술투자조합1호12.50%2026-06-08 · 증감 +12.50%p
- 수피쇼 신기술투자조합1호11.12%2026-05-07 · 증감 +11.12%p
- 알파벳파트너스7.09%2026-05-08 · 증감 +7.09%p
Connections
AI-extracted related companies · for reference
Customers
서울대병원삼성서울병원서울아산병원
Competitors
Same theme
Cancer diagnosticsLiquid biopsy
Recent filings
Celemics's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
About Celemics
- What technical signals does Celemics (331920) have?
- Celemics current technical signals: no active technical signal.
- Is Celemics a cup-and-handle pattern?
- No. Celemics has no valid cup-and-handle signal right now.
- What are Celemics's financials and valuation?
- Celemics's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy